The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome [0.03%]
唐氏综合症患者先天性心脏病对阿尔茨海默病发病时间的影响
Julianne G Clina,Brian C Helsel,Sigan L Hartley et al.
Julianne G Clina et al.
Introduction: The incidence of Alzheimer's disease (AD) in Down syndrome (DS) exceeds 90%. Approximately 50% of people with DS have congenital heart disease (CHD). Having CHD increases risk for early-onset AD in populatio...
Real-world experience with lecanemab therapy for Alzheimer's disease in the Intermountain West [0.03%]
乐克奈单抗治疗阿尔茨海默病在内陆山区的真实世界经验
Bethany C Curd,Camilla Zubrick,Christine J Cliatt Brown et al.
Bethany C Curd et al.
Introduction: Lecanemab is a monoclonal antibody targeting amyloid plaques that has been approved for the treatment of early symptomatic Alzheimer's disease. Here, we report on the clinical history and outcomes of the fir...
Factors associated with discordant visual and quantitative amyloid PET results [0.03%]
导致视觉和定量分析结果不一致的因素
Jasmin E Guevara,Emily F Matusz,Wei-En Wang et al.
Jasmin E Guevara et al.
Introduction: Factors underlying discordant visual and quantitative amyloid beta-positron emission tomography (Aβ-PET) results and their clinical implications are not well understood. ...
Effect of antipsychotic medication use and type on mortality and cardiovascular risks in nursing home patients with dementia [0.03%]
抗精神病药物使用及其类型对痴呆的住院患者的死亡率和心血管风险的影响
Hamid R Okhravi,Fang Fang,Melissa P Hunter et al.
Hamid R Okhravi et al.
Introduction: Antipsychotic medication (APM) use in nursing home (NH) patients with dementia is common but carries risks. This study assessed the association between APM use and mortality, stroke, and myocardial infarctio...
Characterizing Japanese older adults without dementia by amyloid PET status: A comparative study of amyloid-positive and amyloid-negative groups from Japanese trial-ready cohort study [0.03%]
日本Tau临床起始队列中PET淀粉样蛋白阴性和阳性但未痴呆的老年人特征：一项比较研究
Saki Nakashima,Kenichiro Sato,Yoshiki Niimi et al.
Saki Nakashima et al.
Introduction: This study aimed to identify demographic and cognitive differences based on amyloid status in older Japanese adults without dementia, addressing the lack of data in East Asian populations for early Alzheimer...
The use of fully immersive virtual reality for screening neurodegenerative diseases: A systematic review of behavioral and diagnostic outcomes [0.03%]
完全沉浸式虚拟现实筛查神经退行性疾病的使用：行为和诊断结果的系统回顾
Zhao Liu,Daniele Soria,Daniel Jie Lai et al.
Zhao Liu et al.
Early detection of Alzheimer's disease (AD), Parkinson's disease (PD), and mild cognitive impairment (MCI) is crucial for timely intervention. Traditional cognitive screening tools lack ecological validity and sensitivity. Virtual reality (...
Procrastination as a marker of cognitive decline: Evidence from longitudinal transitions in the older adult population [0.03%]
拖延作为认知能力下降的标志：来自老年人大样本纵向研究的证据
Cormac Monaghan,Rafael de Andrade Moral,Michelle Kelly et al.
Cormac Monaghan et al.
Introduction: Cognitive decline is a global health concern, making the identification of early, modifiable risk factors essential. While apathy is a recognized prodromal marker, procrastination may also signal early execu...
Motor, not cognitive, performance relates to amyloid status in normal older adults [0.03%]
正常的老年人中，电机功能而非认知功能与淀粉样蛋白状况相关
Amanda Cook Maher,Savannah Rose,Kelly N DuBois et al.
Amanda Cook Maher et al.
Introduction: The National Insitutes of Health Toolbox (NIHTB) measures may be useful for Alzheimer's disease (AD) risk detection. This study investigates whether cognitively normal older adults with and without elevated ...
The relationship between cognitive screeners and everyday functioning in amyloid-positive participants from the Amsterdam Dementia Cohort [0.03%]
氨斯特丹痴呆症队列中淀粉样蛋白阳性受试者的认知筛查与日常生活能力之间的关系
Angela van der Putten-Toorenburg,Elke Butterbrod,Benjamin D Schalet et al.
Angela van der Putten-Toorenburg et al.
Introduction: We explored the relationship between cognitive screening outcomes and everyday functioning in Alzheimer's disease (AD). Methods: ...
Increased transmembrane protein 119 (TMEM119) levels in the cerebrospinal fluid of patients with mild cognitive impairment due to Alzheimer's disease suggest early microglial involvement [0.03%]
阿尔茨海默病轻度认知障碍患者脑脊液中跨膜蛋白119(TMEM119)水平升高提示早期小胶质细胞参与
Paula Klassen,Christoforos Alexudis,Veronika Klose et al.
Paula Klassen et al.
Introduction: We aimed to evaluate the potential of the microglial marker transmembrane protein 119 (TMEM119) in the cerebrospinal fluid (CSF) as a (differential) diagnostic biomarker for neurodegenerative diseases. ...